Frederik W van Delft
Overview
Explore the profile of Frederik W van Delft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bell H, Blair H, Jepson Gosling S, Galler M, Astley D, Moorman A, et al.
Leukemia
. 2024 Apr;
38(6):1223-1235.
PMID: 38600316
Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential therapeutic strategy for the majority of ALL....
2.
Masic D, Bell H, van Delft F, Irving J
Haematologica
. 2024 Feb;
109(7):2316-2320.
PMID: 38385269
No abstract available.
3.
De Coninck S, De Smedt R, Lintermans B, Reunes L, Kosasih H, Reekmans A, et al.
Haematologica
. 2023 Nov;
109(5):1373-1384.
PMID: 37941480
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are rare aggressive hematologic malignancies. Current treatment consists of intensive chemotherapy leading to 80% overall survival but is associated with...
4.
Bell H, Blair H, Singh M, Moorman A, Heidenreich O, van Delft F, et al.
Cancer Cell Int
. 2023 Sep;
23(1):202.
PMID: 37715172
Background: Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes. Targeted inhibition of WEE1 with small-molecule inhibitor...
5.
van Delft F, Bailey S, Skinner R, Shenton G, Carey P, Campbell-Hewson Q, et al.
Pediatr Blood Cancer
. 2023 May;
:e30451.
PMID: 37246497
No abstract available.
6.
Masic D, Fee K, Bell H, Case M, Witherington G, Lansbury S, et al.
Haematologica
. 2022 Nov;
108(4):981-992.
PMID: 36420798
Persistence of residual disease in acute lymphoblastic leukemia (ALL) during the initial stages of chemotherapy is associated with inferior survival. To better understand clonal evolution and mechanisms of chemoresistance, we...
7.
Bomken S, Enshaei A, Schwalbe E, Mikulasova A, Dai Y, Zaka M, et al.
Haematologica
. 2022 Apr;
108(3):717-731.
PMID: 35484682
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized treatment schedules...
8.
Mansur M, Furness C, Nakjang S, Enshaei A, Alpar D, Colman S, et al.
Cancer Med
. 2021 Jun;
10(14):4864-4873.
PMID: 34080325
Background: Treatment on risk adapted intensive pediatric protocols has improved outcome for teenagers and young adults (TYA) with T-cell acute lymphoblastic leukemia (T-ALL). Understanding the biology of disease in this...
9.
Matthijssens F, Sharma N, Nysus M, Nickl C, Kang H, Perez D, et al.
J Clin Invest
. 2021 Feb;
131(6).
PMID: 33555272
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with inferior outcome compared with that of B cell ALL. Here, we show that Runt-related transcription factor 2 (RUNX2)...
10.
Moorman A, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, et al.
Br J Haematol
. 2020 Sep;
191(5):844-851.
PMID: 32926422
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD...